<!DOCTYPE pdf2xml SYSTEM "pdf2xml.dtd">
<pdf2xml producer="poppler" version="23.04.0">
<page number="1" position="absolute" top="0" left="0" height="792" width="612">
	<fontspec id="font0" size="9" family="Arial,Italic" color="#000000"/>
	<fontspec id="font1" size="9" family="Arial" color="#000000"/>
	<fontspec id="font2" size="9" family="Arial,Bold" color="#000000"/>
	<fontspec id="font3" size="7" family="Arial,Italic" color="#000000"/>
	<fontspec id="font4" size="10" family="Giovanni-Book" color="#000000"/>
	<fontspec id="font5" size="7" family="Giovanni-Book" color="#000000"/>
	<fontspec id="font6" size="11" family="GillSans,Bold" color="#000000"/>
	<fontspec id="font7" size="10" family="Symbol" color="#000000"/>
	<fontspec id="font8" size="10" family="Giovanni-BookItalic,Italic" color="#000000"/>
<text top="41" left="55" width="82" height="10" font="font0" id="p1_t1" reading_order_no="0" segment_no="0" tag_type="title"><i>Medical Immunology</i></text>
<text top="41" left="138" width="28" height="10" font="font1" id="p1_t2" reading_order_no="1" segment_no="0" tag_type="title"> 2006, </text>
<text top="41" left="165" width="5" height="10" font="font2" id="p1_t3" reading_order_no="2" segment_no="0" tag_type="title"><b>5</b></text>
<text top="41" left="170" width="7" height="10" font="font1" id="p1_t4" reading_order_no="3" segment_no="0" tag_type="title">:4</text>
<text top="41" left="384" width="170" height="10" font="font1" id="p1_t5" reading_order_no="4" segment_no="1" tag_type="text">http://www.medimmunol.com/content/5/1/4</text>
<text top="756" left="508" width="46" height="10" font="font1" id="p1_t6" reading_order_no="157" segment_no="11" tag_type="text">Page 5 of 8</text>
<text top="769" left="432" width="122" height="8" font="font3" id="p1_t7" reading_order_no="158" segment_no="12" tag_type="text"><i>(page number not for citation purposes)</i></text>
<text top="87" left="55" width="241" height="9" font="font4" id="p1_t8" reading_order_no="5" segment_no="2" tag_type="text">phagocytic vacuole. Thus, the role of ROS in the killing</text>
<text top="98" left="55" width="241" height="9" font="font4" id="p1_t9" reading_order_no="6" segment_no="2" tag_type="text">process is not as direct as previously thought, although,</text>
<text top="110" left="55" width="241" height="9" font="font4" id="p1_t10" reading_order_no="7" segment_no="2" tag_type="text">ROS are necessary to increase phagosomal osmolarity.</text>
<text top="122" left="55" width="241" height="9" font="font4" id="p1_t11" reading_order_no="8" segment_no="2" tag_type="text">Mice made deficient in neutrophil-granule proteases, but</text>
<text top="134" left="55" width="241" height="9" font="font4" id="p1_t12" reading_order_no="9" segment_no="2" tag_type="text">normal in respect of superoxide production and iodinat-</text>
<text top="145" left="55" width="241" height="9" font="font4" id="p1_t13" reading_order_no="10" segment_no="2" tag_type="text">ing capacity, were unable to resist staphylococcal and can-</text>
<text top="157" left="55" width="241" height="9" font="font4" id="p1_t14" reading_order_no="11" segment_no="2" tag_type="text">didal infections, suggesting that proteases are primarily</text>
<text top="169" left="55" width="241" height="9" font="font4" id="p1_t15" reading_order_no="12" segment_no="2" tag_type="text">responsible for the destruction of the bacteria [<a href="">48]. </a>Fur-</text>
<text top="181" left="55" width="241" height="9" font="font4" id="p1_t16" reading_order_no="13" segment_no="2" tag_type="text">ther research then showed that microbial killing and</text>
<text top="192" left="55" width="175" height="9" font="font4" id="p1_t17" reading_order_no="14" segment_no="2" tag_type="text">digestion were abolished when the BK</text>
<text top="197" left="230" width="10" height="6" font="font5" id="p1_t18" reading_order_no="15" segment_no="2" tag_type="text">Ca </text>
<text top="192" left="242" width="55" height="9" font="font4" id="p1_t19" reading_order_no="16" segment_no="2" tag_type="text">channel was</text>
<text top="204" left="55" width="241" height="9" font="font4" id="p1_t20" reading_order_no="17" segment_no="2" tag_type="text">blocked, revealing an essential and unexpected function</text>
<text top="216" left="55" width="39" height="9" font="font4" id="p1_t21" reading_order_no="18" segment_no="2" tag_type="text">for this K</text>
<text top="215" left="94" width="6" height="6" font="font5" id="p1_t22" reading_order_no="19" segment_no="2" tag_type="text">+ </text>
<text top="216" left="99" width="173" height="9" font="font4" id="p1_t23" reading_order_no="20" segment_no="2" tag_type="text">channel in the microbicidal proc<a href="">ess [48</a>].</text>
<text top="240" left="55" width="171" height="10" font="font6" id="p1_t24" reading_order_no="21" segment_no="4" tag_type="title"><b>Defective inflammatory responses</b></text>
<text top="251" left="55" width="241" height="9" font="font4" id="p1_t25" reading_order_no="22" segment_no="5" tag_type="text">In addition to recurrent life-threatening infections,</text>
<text top="263" left="55" width="241" height="9" font="font4" id="p1_t26" reading_order_no="23" segment_no="5" tag_type="text">patients often develop sterile granulomas in hollow</text>
<text top="275" left="55" width="241" height="9" font="font4" id="p1_t27" reading_order_no="24" segment_no="5" tag_type="text">organs, liver, lymphoid tissue and skin, without clinical</text>
<text top="286" left="55" width="241" height="9" font="font4" id="p1_t28" reading_order_no="25" segment_no="5" tag_type="text">evidence of infect<a href="">ions [49]</a>. The mechanisms involved in</text>
<text top="298" left="55" width="241" height="9" font="font4" id="p1_t29" reading_order_no="26" segment_no="5" tag_type="text">this aberrant inflammatory response are unknown.</text>
<text top="310" left="55" width="241" height="9" font="font4" id="p1_t30" reading_order_no="27" segment_no="5" tag_type="text">Inflammatory responses are finely balanced between pro-</text>
<text top="322" left="55" width="241" height="9" font="font4" id="p1_t31" reading_order_no="28" segment_no="5" tag_type="text">inflammatory and anti-inflammatory mediators and are</text>
<text top="333" left="55" width="241" height="9" font="font4" id="p1_t32" reading_order_no="29" segment_no="5" tag_type="text">important in generating an effective primary immune</text>
<text top="345" left="55" width="241" height="9" font="font4" id="p1_t33" reading_order_no="30" segment_no="5" tag_type="text">response and in clearing infection. Cultured cells from</text>
<text top="357" left="55" width="241" height="9" font="font4" id="p1_t34" reading_order_no="31" segment_no="5" tag_type="text">CGD patients have been shown to be deficient in their</text>
<text top="369" left="55" width="241" height="9" font="font4" id="p1_t35" reading_order_no="32" segment_no="5" tag_type="text">ability to produce anti-inflammatory mediators [<a href="">50]</a> and</text>
<text top="380" left="55" width="241" height="9" font="font4" id="p1_t36" reading_order_no="33" segment_no="5" tag_type="text">that neutrophils from these patients are defective in their</text>
<text top="392" left="55" width="241" height="9" font="font4" id="p1_t37" reading_order_no="34" segment_no="5" tag_type="text">ability to expose phosphatidylserine (PS), which is a rec-</text>
<text top="404" left="55" width="241" height="9" font="font4" id="p1_t38" reading_order_no="35" segment_no="5" tag_type="text">ognition factor for phagocytic cells to clear apoptotic cell</text>
<text top="416" left="55" width="241" height="9" font="font4" id="p1_t39" reading_order_no="36" segment_no="5" tag_type="text">bodies. The externalized PS molecules on apoptotic cells,</text>
<text top="427" left="55" width="241" height="9" font="font4" id="p1_t40" reading_order_no="37" segment_no="5" tag_type="text">and subsequent internalization and degradation of apop-</text>
<text top="439" left="55" width="241" height="9" font="font4" id="p1_t41" reading_order_no="38" segment_no="5" tag_type="text">totic cells, is crucial to prevent the activation of an inflam-</text>
<text top="451" left="55" width="241" height="9" font="font4" id="p1_t42" reading_order_no="39" segment_no="5" tag_type="text">matory response and persistence of inflammatory cells</text>
<text top="463" left="55" width="241" height="9" font="font4" id="p1_t43" reading_order_no="40" segment_no="5" tag_type="text">that do not undergo apoptosis and are not phagocytosed</text>
<text top="474" left="55" width="241" height="9" font="font4" id="p1_t44" reading_order_no="41" segment_no="5" tag_type="text">leads to an increase of necrosis and release of toxic granule</text>
<text top="486" left="55" width="241" height="9" font="font4" id="p1_t45" reading_order_no="42" segment_no="5" tag_type="text">contents that can cause chronic inflammation. Recently,</text>
<text top="498" left="55" width="241" height="9" font="font4" id="p1_t46" reading_order_no="43" segment_no="5" tag_type="text">we have shown that the rate of phagocytosis of apoptotic</text>
<text top="510" left="55" width="241" height="9" font="font4" id="p1_t47" reading_order_no="44" segment_no="5" tag_type="text">CGD neutrophils is also reduced (unpublished observa-</text>
<text top="521" left="55" width="241" height="9" font="font4" id="p1_t48" reading_order_no="45" segment_no="5" tag_type="text">tions). It is not known why this occurs and further studies</text>
<text top="533" left="55" width="241" height="9" font="font4" id="p1_t49" reading_order_no="46" segment_no="5" tag_type="text">of the mechanisms of neutrophil apoptosis are necessary</text>
<text top="545" left="55" width="241" height="9" font="font4" id="p1_t50" reading_order_no="47" segment_no="5" tag_type="text">to understand the pathophysiology of its deficiency in</text>
<text top="557" left="55" width="241" height="9" font="font4" id="p1_t51" reading_order_no="48" segment_no="5" tag_type="text">CGD. Failure to successfully resolve inflammation can</text>
<text top="568" left="55" width="241" height="9" font="font4" id="p1_t52" reading_order_no="49" segment_no="5" tag_type="text">underlie the persistent inflammatory responses in CGD</text>
<text top="580" left="55" width="241" height="9" font="font4" id="p1_t53" reading_order_no="50" segment_no="5" tag_type="text">patients, as manifested by colitis, urinary tract obstruc-</text>
<text top="592" left="55" width="241" height="9" font="font4" id="p1_t54" reading_order_no="51" segment_no="5" tag_type="text">tion, dysphagia, gastric outlet obstruction and chori-</text>
<text top="604" left="55" width="40" height="9" font="font4" id="p1_t55" reading_order_no="52" segment_no="5" tag_type="text">oretinitis.</text>
<text top="627" left="55" width="181" height="10" font="font6" id="p1_t56" reading_order_no="53" segment_no="8" tag_type="title"><b>Interferon-gamma therapy for CGD</b></text>
<text top="639" left="55" width="241" height="9" font="font4" id="p1_t57" reading_order_no="54" segment_no="9" tag_type="text">In the late 1980s the potential of interferon gamma was</text>
<text top="651" left="55" width="241" height="9" font="font4" id="p1_t58" reading_order_no="55" segment_no="9" tag_type="text">investigated as a prophylactic therapeutic agent for CGD</text>
<text top="662" left="55" width="241" height="9" font="font4" id="p1_t59" reading_order_no="56" segment_no="9" tag_type="text">as preliminary studies in CGD patients demonstrated that</text>
<text top="674" left="55" width="241" height="9" font="font4" id="p1_t60" reading_order_no="57" segment_no="9" tag_type="text">brief in vitro or in vivo administration of recombinant</text>
<text top="686" left="55" width="19" height="9" font="font4" id="p1_t61" reading_order_no="58" segment_no="9" tag_type="text">IFN-</text>
<text top="684" left="74" width="4" height="13" font="font7" id="p1_t62" reading_order_no="59" segment_no="9" tag_type="text">γ</text>
<text top="686" left="78" width="29" height="9" font="font4" id="p1_t63" reading_order_no="60" segment_no="9" tag_type="text"> (rIFN-</text>
<text top="684" left="106" width="4" height="13" font="font7" id="p1_t64" reading_order_no="61" segment_no="9" tag_type="text">γ</text>
<text top="686" left="110" width="165" height="9" font="font4" id="p1_t65" reading_order_no="62" segment_no="9" tag_type="text">) significantly enhanced phagocyte O2-</text>
<text top="685" left="275" width="3" height="6" font="font5" id="p1_t66" reading_order_no="63" segment_no="9" tag_type="text">. </text>
<text top="686" left="278" width="18" height="9" font="font4" id="p1_t67" reading_order_no="64" segment_no="9" tag_type="text">pro-</text>
<text top="698" left="55" width="54" height="9" font="font4" id="p1_t68" reading_order_no="65" segment_no="9" tag_type="text">duction and </text>
<text top="698" left="109" width="88" height="9" font="font8" id="p1_t69" reading_order_no="66" segment_no="9" tag_type="text"><i>Staphylococcus aureus </i></text>
<text top="698" left="198" width="99" height="9" font="font4" id="p1_t70" reading_order_no="67" segment_no="9" tag_type="text">bacterial killing. In two</text>
<text top="709" left="55" width="181" height="9" font="font4" id="p1_t71" reading_order_no="68" segment_no="9" tag_type="text">patients with variant X-linked CGD, rIFN-</text>
<text top="707" left="236" width="4" height="13" font="font7" id="p1_t72" reading_order_no="69" segment_no="9" tag_type="text">γ</text>
<text top="709" left="240" width="56" height="9" font="font4" id="p1_t73" reading_order_no="70" segment_no="9" tag_type="text"> treatment in</text>
<text top="721" left="55" width="241" height="9" font="font4" id="p1_t74" reading_order_no="71" segment_no="9" tag_type="text">vivo was also associated with increased spectral levels of</text>
<text top="87" left="313" width="111" height="9" font="font4" id="p1_t75" reading_order_no="72" segment_no="3" tag_type="text">neutrophil cytochrome-b</text>
<text top="91" left="424" width="13" height="6" font="font5" id="p1_t76" reading_order_no="73" segment_no="3" tag_type="text">558 </text>
<text top="87" left="441" width="113" height="9" font="font4" id="p1_t77" reading_order_no="74" segment_no="3" tag_type="text"><a href="">[51]</a>. Subsequent studies</text>
<text top="98" left="313" width="219" height="9" font="font4" id="p1_t78" reading_order_no="75" segment_no="3" tag_type="text">found little evidence for transient increases in O2-</text>
<text top="98" left="532" width="3" height="6" font="font5" id="p1_t79" reading_order_no="76" segment_no="3" tag_type="text">. </text>
<text top="98" left="536" width="18" height="9" font="font4" id="p1_t80" reading_order_no="77" segment_no="3" tag_type="text">pro-</text>
<text top="110" left="313" width="101" height="9" font="font4" id="p1_t81" reading_order_no="78" segment_no="3" tag_type="text">duction following rIFN-</text>
<text top="108" left="414" width="4" height="13" font="font7" id="p1_t82" reading_order_no="79" segment_no="3" tag_type="text">γ</text>
<text top="110" left="418" width="85" height="9" font="font4" id="p1_t83" reading_order_no="80" segment_no="3" tag_type="text"> therapy, where O2-</text>
<text top="110" left="503" width="4" height="6" font="font5" id="p1_t84" reading_order_no="81" segment_no="3" tag_type="text">. </text>
<text top="110" left="507" width="47" height="9" font="font4" id="p1_t85" reading_order_no="82" segment_no="3" tag_type="text">production</text>
<text top="122" left="313" width="241" height="9" font="font4" id="p1_t86" reading_order_no="83" segment_no="3" tag_type="text">was not sustained or associated with any change in cyto-</text>
<text top="134" left="313" width="41" height="9" font="font4" id="p1_t87" reading_order_no="84" segment_no="3" tag_type="text">chrome-b</text>
<text top="138" left="354" width="13" height="6" font="font5" id="p1_t88" reading_order_no="85" segment_no="3" tag_type="text">558 </text>
<text top="134" left="367" width="148" height="9" font="font4" id="p1_t89" reading_order_no="86" segment_no="3" tag_type="text"><a href="">levels [52]</a>. In some patients, rIFN-</text>
<text top="131" left="515" width="4" height="13" font="font7" id="p1_t90" reading_order_no="87" segment_no="3" tag_type="text">γ</text>
<text top="134" left="519" width="35" height="9" font="font4" id="p1_t91" reading_order_no="88" segment_no="3" tag_type="text"> therapy</text>
<text top="145" left="313" width="241" height="9" font="font4" id="p1_t92" reading_order_no="89" segment_no="3" tag_type="text">was associated with the appearance of a small subset of</text>
<text top="157" left="313" width="241" height="9" font="font4" id="p1_t93" reading_order_no="90" segment_no="3" tag_type="text">circulating monocytes (1% to 20%) that were NBT-posi-</text>
<text top="169" left="313" width="241" height="9" font="font4" id="p1_t94" reading_order_no="91" segment_no="3" tag_type="text">tive, suggesting that one possible mechanism by which</text>
<text top="181" left="313" width="22" height="9" font="font4" id="p1_t95" reading_order_no="92" segment_no="3" tag_type="text">rIFN-</text>
<text top="178" left="335" width="4" height="13" font="font7" id="p1_t96" reading_order_no="93" segment_no="3" tag_type="text">γ</text>
<text top="181" left="339" width="215" height="9" font="font4" id="p1_t97" reading_order_no="94" segment_no="3" tag_type="text"> may benefit CGD patients was by partially correct-</text>
<text top="192" left="313" width="241" height="9" font="font4" id="p1_t98" reading_order_no="95" segment_no="3" tag_type="text">ing the respiratory burst defect in a subset of monocytes.</text>
<text top="204" left="313" width="126" height="9" font="font4" id="p1_t99" reading_order_no="96" segment_no="3" tag_type="text">Although it seemed that rIFN-</text>
<text top="202" left="439" width="4" height="13" font="font7" id="p1_t100" reading_order_no="97" segment_no="3" tag_type="text">γ</text>
<text top="204" left="443" width="111" height="9" font="font4" id="p1_t101" reading_order_no="98" segment_no="3" tag_type="text"> therapy in the vast major-</text>
<text top="216" left="313" width="241" height="9" font="font4" id="p1_t102" reading_order_no="99" segment_no="3" tag_type="text">ity of CGD patients was not due to enhanced neutrophil</text>
<text top="228" left="313" width="208" height="9" font="font4" id="p1_t103" reading_order_no="100" segment_no="3" tag_type="text">NADPH oxidase activity, the mechanism of rIFN-</text>
<text top="225" left="521" width="4" height="13" font="font7" id="p1_t104" reading_order_no="101" segment_no="3" tag_type="text">γ</text>
<text top="228" left="525" width="29" height="9" font="font4" id="p1_t105" reading_order_no="102" segment_no="3" tag_type="text"> action</text>
<text top="239" left="313" width="222" height="9" font="font4" id="p1_t106" reading_order_no="103" segment_no="3" tag_type="text">in CGD patients remains unknown. A study by Ahlin </text>
<text top="239" left="535" width="19" height="9" font="font8" id="p1_t107" reading_order_no="104" segment_no="3" tag_type="text"><i>et al.</i></text>
<text top="251" left="313" width="98" height="9" font="font4" id="p1_t108" reading_order_no="105" segment_no="3" tag_type="text"><a href="">[53</a>] showed that rIFN-</text>
<text top="249" left="411" width="4" height="13" font="font7" id="p1_t109" reading_order_no="106" segment_no="3" tag_type="text">γ</text>
<text top="251" left="415" width="139" height="9" font="font4" id="p1_t110" reading_order_no="107" segment_no="3" tag_type="text"> treatment of patients with CGD</text>
<text top="263" left="313" width="241" height="9" font="font4" id="p1_t111" reading_order_no="108" segment_no="3" tag_type="text">was associated with augmented production of nitric oxide</text>
<text top="275" left="313" width="241" height="9" font="font4" id="p1_t112" reading_order_no="109" segment_no="3" tag_type="text">by polymorphonuclear neutrophils. A comprehensive fol-</text>
<text top="286" left="313" width="241" height="9" font="font4" id="p1_t113" reading_order_no="110" segment_no="3" tag_type="text">low up study of 76 patients with CGD who received rIFN-</text>
<text top="296" left="313" width="4" height="13" font="font7" id="p1_t114" reading_order_no="111" segment_no="3" tag_type="text">γ</text>
<text top="298" left="317" width="237" height="9" font="font4" id="p1_t115" reading_order_no="112" segment_no="3" tag_type="text"> found that its prolonged use in patients with CGD</text>
<text top="310" left="313" width="241" height="9" font="font4" id="p1_t116" reading_order_no="113" segment_no="3" tag_type="text">appeared to be safe and showed persistent reduction in</text>
<text top="322" left="313" width="241" height="9" font="font4" id="p1_t117" reading_order_no="114" segment_no="3" tag_type="text">the frequency of serious infection and mo<a href="">rtality [54</a>].</text>
<text top="333" left="313" width="205" height="9" font="font4" id="p1_t118" reading_order_no="115" segment_no="3" tag_type="text">Recent studies looking at the cytochrome-b</text>
<text top="338" left="518" width="13" height="6" font="font5" id="p1_t119" reading_order_no="116" segment_no="3" tag_type="text">558 </text>
<text top="333" left="535" width="20" height="9" font="font4" id="p1_t120" reading_order_no="117" segment_no="3" tag_type="text">gene</text>
<text top="345" left="313" width="241" height="9" font="font4" id="p1_t121" reading_order_no="118" segment_no="3" tag_type="text">expression in Braz<a href="">il [55</a>] and Japan <a href="">[56] </a>found increased</text>
<text top="357" left="313" width="241" height="9" font="font4" id="p1_t122" reading_order_no="119" segment_no="3" tag_type="text">total messenger RNA (mRNA) levels in the CGD patients'</text>
<text top="369" left="313" width="108" height="9" font="font4" id="p1_t123" reading_order_no="120" segment_no="3" tag_type="text">cells suggesting that rIFN-</text>
<text top="366" left="422" width="4" height="13" font="font7" id="p1_t124" reading_order_no="121" segment_no="3" tag_type="text">γ</text>
<text top="369" left="426" width="129" height="9" font="font4" id="p1_t125" reading_order_no="122" segment_no="3" tag_type="text"> improved mRNA splicing and</text>
<text top="380" left="313" width="88" height="9" font="font4" id="p1_t126" reading_order_no="123" segment_no="3" tag_type="text">concluded that rIFN-</text>
<text top="378" left="401" width="4" height="13" font="font7" id="p1_t127" reading_order_no="124" segment_no="3" tag_type="text">γ</text>
<text top="380" left="405" width="149" height="9" font="font4" id="p1_t128" reading_order_no="125" segment_no="3" tag_type="text"> partially corrects a nuclear process-</text>
<text top="392" left="313" width="241" height="9" font="font4" id="p1_t129" reading_order_no="126" segment_no="3" tag_type="text">ing defect. These studies have lead to the consensus that</text>
<text top="404" left="313" width="241" height="9" font="font4" id="p1_t130" reading_order_no="127" segment_no="3" tag_type="text">only rare variants with splice site mutations can be</text>
<text top="416" left="313" width="87" height="9" font="font4" id="p1_t131" reading_order_no="128" segment_no="3" tag_type="text">improved with rIFN-</text>
<text top="413" left="400" width="4" height="13" font="font7" id="p1_t132" reading_order_no="129" segment_no="3" tag_type="text">γ</text>
<text top="416" left="404" width="62" height="9" font="font4" id="p1_t133" reading_order_no="130" segment_no="3" tag_type="text"> therapy. rIFN-</text>
<text top="413" left="466" width="4" height="13" font="font7" id="p1_t134" reading_order_no="131" segment_no="3" tag_type="text">γ</text>
<text top="416" left="470" width="84" height="9" font="font4" id="p1_t135" reading_order_no="132" segment_no="3" tag_type="text"> therapy is relatively</text>
<text top="427" left="313" width="241" height="9" font="font4" id="p1_t136" reading_order_no="133" segment_no="3" tag_type="text">expensive due to the high cost of recombinant human</text>
<text top="439" left="313" width="241" height="9" font="font4" id="p1_t137" reading_order_no="134" segment_no="3" tag_type="text">interferons, the large doses and lengthy course of admin-</text>
<text top="451" left="313" width="241" height="9" font="font4" id="p1_t138" reading_order_no="135" segment_no="3" tag_type="text">istration necessary to achieve maximum response rates in</text>
<text top="463" left="313" width="241" height="9" font="font4" id="p1_t139" reading_order_no="136" segment_no="3" tag_type="text">recipients, and is not routinely administered prophylacti-</text>
<text top="474" left="313" width="66" height="9" font="font4" id="p1_t140" reading_order_no="137" segment_no="3" tag_type="text">cally in Europe.</text>
<text top="498" left="313" width="80" height="10" font="font6" id="p1_t141" reading_order_no="138" segment_no="6" tag_type="title"><b>A cure for CGD</b></text>
<text top="510" left="313" width="241" height="9" font="font4" id="p1_t142" reading_order_no="139" segment_no="7" tag_type="text">Following the successful use of allogeneic bone marrow</text>
<text top="521" left="313" width="241" height="9" font="font4" id="p1_t143" reading_order_no="140" segment_no="7" tag_type="text">transplants to treat children with severe combined</text>
<text top="533" left="313" width="241" height="9" font="font4" id="p1_t144" reading_order_no="141" segment_no="7" tag_type="text">immune deficiency [<a href="">57]. G</a>oudemand and colleagu<a href="">es [58]</a></text>
<text top="545" left="313" width="241" height="9" font="font4" id="p1_t145" reading_order_no="142" segment_no="7" tag_type="text">made the first attempt to treat a case of CGD using bone</text>
<text top="557" left="313" width="241" height="9" font="font4" id="p1_t146" reading_order_no="143" segment_no="7" tag_type="text">marrow transplantation (BMT). Although in this case the</text>
<text top="568" left="313" width="241" height="9" font="font4" id="p1_t147" reading_order_no="144" segment_no="7" tag_type="text">transplant failed after two months due to tissue rejection</text>
<text top="580" left="313" width="241" height="9" font="font4" id="p1_t148" reading_order_no="145" segment_no="7" tag_type="text">recent advances in BMT expertise and technology have led</text>
<text top="592" left="313" width="241" height="9" font="font4" id="p1_t149" reading_order_no="146" segment_no="7" tag_type="text">to BMT becoming a successful treatment option for CGD</text>
<text top="604" left="313" width="241" height="9" font="font4" id="p1_t150" reading_order_no="147" segment_no="7" tag_type="text">patients. A recent review of cases revealed that 20 of 24</text>
<text top="615" left="313" width="241" height="9" font="font4" id="p1_t151" reading_order_no="148" segment_no="7" tag_type="text">CGD patients are alive and disease free 1–7 years after</text>
<text top="627" left="313" width="241" height="9" font="font4" id="p1_t152" reading_order_no="149" segment_no="7" tag_type="text">transp<a href="">lant [59]. BMT can be success</a>fully performed for</text>
<text top="639" left="313" width="241" height="9" font="font4" id="p1_t153" reading_order_no="150" segment_no="7" tag_type="text">CGD and remains an attractive option for children who</text>
<text top="651" left="313" width="241" height="9" font="font4" id="p1_t154" reading_order_no="151" segment_no="7" tag_type="text">have an HLA matched sibling donor and useful in selected</text>
<text top="662" left="313" width="241" height="9" font="font4" id="p1_t155" reading_order_no="152" segment_no="7" tag_type="text">very severe cases in which prophylactic therapy is prob-</text>
<text top="674" left="313" width="241" height="9" font="font4" id="p1_t156" reading_order_no="153" segment_no="7" tag_type="text">lematic, although in many cases donors can be hard to</text>
<text top="686" left="313" width="20" height="9" font="font4" id="p1_t157" reading_order_no="154" segment_no="7" tag_type="text">find.</text>
<text top="709" left="313" width="241" height="9" font="font4" id="p1_t158" reading_order_no="155" segment_no="10" tag_type="text">Gene therapy involves the permanent genetic correction</text>
<text top="721" left="313" width="241" height="9" font="font4" id="p1_t159" reading_order_no="156" segment_no="10" tag_type="text">of hematopoietic stem cells in which a vector is used to</text>
</page>
</pdf2xml>
